Streetbeat News

Stock Prices

CLNN

Clene Inc. has announced a $7.3 million registered direct offering and concurrent private placements, issuing 742,626 shares and warrants priced at market under Nasdaq rules.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:31 pm

APLD

BTBT

BTDR

CIFR

CRVS

HUT

MSTR

STLA

VERO

Several major stocks, including Stellantis, MicroStrategy, and Bit Digital, are experiencing declines in Monday's pre-market session. Stellantis shares fell sharply after lowering its 2024 operating margin guidance. Other stocks like Bitdeer Technologies, Corvus Pharmaceuticals, and Venus Concept also saw significant pre-market losses.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 12:30 pm

CI

CVS

UNH

CVS Health is under pressure as activist investor Glenview Capital Management plans to meet with executives to discuss operational improvements. Glenview, holding a $700 million position, aims for cost-cutting and restructuring without a breakup. CVS faces challenges with declining earnings and FTC scrutiny over anti-competitive practices.

Portfolio Pulse from Vandana Singh

September 30, 2024 | 12:26 pm

ASST

Asset Entities has announced an at-the-market offering of up to $1.79 million in Class B common stock. This move allows the company to raise capital by selling shares directly into the market at prevailing prices.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:23 pm

WINT

Windtree Therapeutics reported that serious adverse events related to worsening heart failure occurred less frequently in patients treated with Istaroxime compared to those given a placebo. The rates were 5.3% for the Istaroxime group versus 18.2% for the placebo group.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:21 pm

WINT

Windtree Therapeutics announced positive Phase 2b clinical results for istaroxime, showing significant improvements in cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint, with istaroxime outperforming placebo in improving systolic blood pressure.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:17 pm

EMKR

Emcore shares rise as Mobix Labs offers to acquire the company for $3.80 per share in an all-cash deal.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:16 pm

KZR

Trading for a certain asset has been halted at 8:15:00 a.m. ET due to pending news. This could indicate significant upcoming information that may impact the asset's price.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:15 pm

RLYB

Rallybio Corporation presented nonclinical data on ENPP1 inhibition as a therapeutic approach for hypophosphatasia at the ASBMR 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:13 pm

CCG

Cheche Group's CEO and Chairman, Lei Zhang, has purchased Class A shares in the open market, indicating confidence in the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:09 pm